Methcathinone: An initial study of its effects on monoaminergic systems

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 3, 1996, Pages 1066-1072

  Gygi, Melanie P ^a   Gibb, James W ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; DOPAMINE; ENZYME INHIBITOR; MONOMETHYLPROPION; PROPIOPHENONE DERIVATIVE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL; ARTICLE; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

AMINES; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; PROPIOPHENONES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TYROSINE 3-MONOOXYGENASE;

EID: 0030111252     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. BAKHIT, C. AND GIBB, J. W.: Methamphetamine-induced depression of tryptophan hydroxylase: Recovery following acute treatment. Eur. J. Pharmacol. 76: 229-233, 1981.
2. 3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242: 911-916, 1987.
3. COLE, S. O.: Brain mechanisms of amphetamine-induced anorexia, locomotion, and stereotypy: A review. Neurosci. Biobehav. Rev. 2: 89-100, 1978.
4. COMMINS, D. L., VOSMER, G., VIRUS, R. M., WOOLVERTON, W. L., SCHUSTER, C. R. AND SEIDEN, L. S.. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241: 338-345, 1987.
5. CREESE, I. AND IVERSEN, S. D.: The role of forebrain dopamine systems in amphetamine-induced stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Psychopharmacology 39: 345-357, 1974.
6. DAL CASON, T. A.: The identification of cathinone and methcathinone. Microgram 25: 313-329, 1992.
7. ELLISON, G., EISON, M. S., HABERMAN, H. S. AND DANIEL, F.: Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science (Washington D. C.) 201: 276-278, 1978.
8. EMERSON, T. S. AND CISEK, J. E.: Methcathinone: A Russian designer amphetamine infiltrates the rural midwest. Ann. Emerg. Med. 22: 1897-1903, 1993.
9. EMERSON, P. C. AND LINDVALL, O.: Distribution of putative neurotransmitters in the neocortex Neuroscience 4: 1, 1979.
10. FEDERAL REGISTER: 58(198): 53404-53406, October 15, 1993.
11. FULLER, R. W. AND HEMRICK-LUECKE, S. K.: Further studies on the long-term depletion of striatal dopamine in iprindole-treated rats by amphetamine. Neuropharmacology 21: 433-438, 1982.
12. FULLER, R. W. AND HEMRICK-LUECKE, S. K.: Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science 209: 305-307, 1980.
13. GLENNON, R. A.: Discriminative stimulus properties of phenylisopropylamine derivatives. Drug Alcohol Depend. 17: 119-134, 1986.
14. GLENNON, R. A., YOUSIF, M., NAIMAN, N. AND KALIX, P.: Methcathinone: A new and potent amphetamine-like agent. Pharmacol. Biochem. Behav. 26: 547-551, 1987.
15. GLENNON, R. A., YOUNG, R., MARTIN, B. R. AND DAL CASON, T. A.: Methcathinone ('Cat'): An enantiomeric potency comparison. Pharmacol. Biochem. Behav. 50: 601-606, 1995.
16. HANSON, G. R , MATSUDA, L. A. AND GIBB, J. W.: Effects of cocaine on metham-phetamine-induced neurochemical changes: Characterization of cocaine as a monoamine uptake blocker. J. Pharmacol Exp. Ther. 242: 507-513, 1987.
17. HOTCHKISS, A J. AND GIBB, J. W.: Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in the rat brain. J. Pharmacol. Exp. Ther. 214: 257-262, 1980.
18. JOHNSON, M., ELAYAN, I., HANSON, G. R., FOLTZ, R. L., GIBB, J. W. AND LIM, H. K.: Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymetham-phetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261: 447-453, 1992.
19. KAMINSKI, B. J. AND GRIFFITHS, R. R.: Intravenous self-injection of methcathinone in the baboon. Pharmacol. Biochem. Behav. 47: 981-983, 1994.
20. KELLY, P. H.: Drug-induced motor behavior. In Handbook of Psychopharmacology, ed. by L. Iversen, S. Iversen and S. H. Snyder, Vol. 8, pp. 295-331, Plenum Press, New York, 1977.
21. KODA, L. Y. AND GIBE, J. W.: Adrenal and striatal tyrosine hydroxylase activity after methamphetamine J. Pharmacol. Exp Ther. 185: 42-48, 1973.
22. LOREZ, H.: Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci. 28: 911-916, 1981.
23. L'ITALIEN, Y. J., WESTON, J. K. AND PARK, H.: Toxicity studies on AL-464 Research Department, Parke, Davis and Co , December 1954, and methylaminopropiophenone compounds #28802865. U.S. Patent Office. August 13, 1957
24. NAGATSU, T.: Analysis of monoxygenases in catecholamine biosynthesis: Tyrosine hydroxylase and dopamine-beta-hydroxylase. In Methods in Biogenic Amine Research, ed. by S. Parvez, T. Nagatsu, I. Nagatsu and H. Parvez, pp. 329-357, Elsevier Science Publisher B.V., Amsterdam, 1983.
25. NIELSEN, J. A. AND MOORE, K. E.: Measurement of metabolites of dopamine and 5-hyctroxytryptamine in cerebroventricular perfusates of unanesthetized, freely-moving rats: Selective effects of drugs. Pharmacol. Biochem. Behav 16: 131-137, 1982.
26. O'HEARN, E. G., BATTAGLIA, G., DESOUZA, E. B., KUHAR, M. J. AND MOLLIVER, M. E.: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence. J. Neurosci. 8: 2788-2803, 1988.
27. PEAT, M. A., WARREN, P. F., BAKHIT, C AND GIBB, J. W.: The acute effects of methamphetamine, amphetamine and p-chloroamphetamine on the cortical serotonergic system of the rat brain: Evidence for differences in the effects of methamphetamine and amphetamine. Eur. J. Pharmacol. 116: 11-16, 1985.
28. RICAURTE, G. A., SCHUSTER, C. R. AND SEIDEN, L. S.: Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res. 193: 153-163, 1980.
29. RICAURTE, G., BRYAN, G., STRAUSS, L., SEIDEN, L. AND SCHUSTER, C.: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science (Washington, D. C.) 229: 986-988, 1985.
30. RICAURTE, G. A., FORNO, L. S., WILSON, M. A, DELANNEY, L. E., IRWIN, I, MOLLIVER, M. E. AND LANGSTON, J. W.: MDMA selectively damages central serotonergic neurons in the primate. J.A.M.A. 260: 51-55, 1988.
31. ROSEN, D. S.: Methcathinone. J. Adoles. Health 14: 426, 1993.
32. SCHMIDT, C J. AND GIBB, J. W.: Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: Effects of amfonelic acid. Eur. J. Pharmacol. 109: 73-80, 1985.
33. SCHMIDT, C. J., RITTER, J. K., SONSALLA, P. K., HANSON, G. R. AND GIBB, J. W.: Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233: 539-544, 1985.
34. SESSIONS, G., MEYERHOFF, J., KANT, G. J. AND KOOB, G. F.: Effects of lesions of the ventral medial tegmentum on locomotor activity, biogenic amines and response to amphetamine in rats Pharmacol. Biochem. Behav. 12: 603-608, 1980.
35. SHULGIN, A. T.: Psychotomimetic drugs: Structure-activity relationships. In Handbook of Psychopharmacology, Vol. 11: Stimulants, ed. by L. H. Iversen, S. D. Iversen and S. H. Snyder, pg. 243-333, Plenum Press, New York, 1978.
36. SLIKKER, W., JR., ALI, S. F., SCALLET, A. C., FRITH, C. H., NEWPORT, G. D. AND BAILEY, J. R.: Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol. Appl. Pharmacol. 94: 448-457, 1988.
37. SONSALLA, P. K., GIBB, J. W. AND HANSON, G. R.: Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp Ther. 238: 932-937, 1986.
38. STONE, D. M., STAHL, D. M., HANSON, G. R. AND GIBB, J. W.: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128: 41-48, 1986.
39. STONE, D. M., JOHNSON, M., HANSON, G. R. AND GIBB, J. W.: A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol. 134: 245-248, 1987.
40. STONE, D. M., HANSON, G. R. AND GIBB, J. W.: In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J. Neurochem. 53: 572-581, 1989.
41. WOOLVERTON, W. L.: Discriminative stimulus effects of cocaine. In Drug Discrimination: Applications in Drug Abuse Research, ed. by R. A. Glennon, T U. C. Jarbe and J. Frankenheim, pp. 60-74, U.S. Government Printing Office, Washington, D.C., 1991.
42. YOUNG, R. AND GLENNON, R. A.: Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav. 45: 229-231, 1993.
43. ZHINGEL, Y. K., DOVENSKY, B. S. AND CROSSMAN, A.: Ephedrone: 2-Methylamino-1-phenylpropan-1-one (Jeff). J. Forens. Sci. 36: 915-920, 1991.